Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies
Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45—marking a significant milestone...
Tevard Biosciences to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model
Preclinical results demonstrating the potential of Tevard Biosciences' tRNA therapy for Duchenne Muscular Dystrophy (DMD) will be presented.
Tevard Biosciences is a privately held biotechnology...
Satellos Prepares to Launch Phase 2 Clinical Study of SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos Bioscience, a clinical-stage biotechnology company focused on developing regenerative therapies for muscle diseases, has announced at ClinicalTrials.Gov it is preparing to initiate a...
mRNA Studies in DMD Treatment: Future Therapeutic Candidates
Given that FDA-approved exon skipping therapies and gene therapy for Duchenne Muscular Dystrophy, which are known to not produce sufficient levels of dystrophin and...
Miraculous Steroid Vamorolone (Agamree) Could Offer Safer Treatment for DMD
A novel steroid medication that is used to treat Duchenne muscular dystrophy has showed great potential in treating inflammatory conditions including rheumatoid arthritis, according...